Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche To Suspend HIV Research | Contract Pharma

What are you searching for?

Sign in
Breaking News

Roche To Suspend HIV Research

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche plans to suspend its HIV research because pending medicines fail to show significant improvement over existing therapies, according to a company statement. The company also claimed it will “refocus resources within virology on diseases in which the company can deliver substantial improvements over existing medications.” Research scientists currently working in HIV will be reassigned to other activities, according to Linda Dyson, a spokeswoman in Roche’s U.S. office in NJ.
   
The company plans to continue to support its molecular diagnostic tests and drugs already on the market, including the fusion-inhibitor Fuzeon. Roche has partnered with Trimeris, Inc., a NC-based biotech company, to sell Fuzeon, which had sales of $266.8 million last year. The drug has experienced some difficulty in the past because of its high cost, which is approximately $25,000 for a year’s supply.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters